With the identification of novel targets, the number of interventional clinical trials in
ophthalmology has increased. Visual acuity has for a long time been considered the gold …

Retinal gene supplementation therapy such as the first approved one, voretigene
neparvovec, delivers a functioning copy of the missing gene enabling the protein …

Background Voretigene neparvovec is a gene therapeutic agent for treatment of retinal
dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and …

Purpose: Chorioretinal atrophy growth after voretigene neparvovec has been reported
recently with its positive correlation with successful treatment. This finding raised the …

In this retrospective, longitudinal, observational cohort study, we investigated the phenotypic
and genotypic features of retinitis pigmentosa associated with variants in the PDE6B gene …

For many inherited and acquired retinal diseases, reduced night vision is a primary
symptom. Despite this, the clinical testing options for spatially resolved scotopic vision have …

Abstract Background Voretigene neparvovec (Luxturna®) is the first approved gene therapy
for RPE65-linked Leber congenital amaurosis (LCA). Though individual effects are highly …

Purpose: Verifying whether specific genotypes causing retinitis pigmentosa (RP) show
differences in the preservation of rod and cone function measured by chromatic pupil …

Purpose: In this study, chromatic pupil campimetry (CPC) was used to map local functional
degenerative changes of cones and rods in Stargardt disease (STGD1). Methods: 19 …

When we develop a new treatment for retinal diseases, we think about how to design a
clinical trial to show that the new treatment is effective for the targeted retinal diseases. The …